These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21412840)

  • 1. Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease.
    Benincasa D; Pellicano C; Fanciulli A; Pontieri FE
    Mov Disord; 2011 Feb; 26(2):355-7. PubMed ID: 21412840
    [No Abstract]   [Full Text] [Related]  

  • 2. Alteration of eating behaviors in patients with Parkinson's disease: possibly overlooked?
    Miwa H; Kondo T
    Neurocase; 2008; 14(6):480-4. PubMed ID: 19012168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies.
    Hassan A; Bower JH; Kumar N; Matsumoto JY; Fealey RD; Josephs KA; Ahlskog JE
    Parkinsonism Relat Disord; 2011 May; 17(4):260-4. PubMed ID: 21310646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa for the treatment of Parkinson's disease.
    Lewitt PA
    N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
    Friedman JH; Agarwal P; Alcalay R; Black KJ; Chou KL; Cote L; Dayalu P; Frank S; Hartlein J; Hauser RA; Lang AE; Marsh L; Marshall F; Moskowitz C; Ravina B; Riley D; Sanchez-Ramos J; Simon DK; Simuni T; Sutton J; Tuite P; Weintraub D; Zesiewicz T
    Int J Neurosci; 2011 Aug; 121(8):472-6. PubMed ID: 21663381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of panic disorder with bupropion in a patient with Parkinson's disease.
    Gebhardt S; Röttgers H; Bäcker A; Schu U; Krieg JC
    J Clin Pharm Ther; 2008 Oct; 33(5):575-7. PubMed ID: 18834374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 9. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 16. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 17. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is pathological gambling in Parkinson's disease reduced by amantadine?
    Lee JY; Kim HJ; Jeon BS
    Ann Neurol; 2011 Jan; 69(1):213-4; author reply 214-5. PubMed ID: 21280095
    [No Abstract]   [Full Text] [Related]  

  • 19. Ropinirole as compared with levodopa in Parkinson's disease.
    Hiner BC; Earnhart M
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001684
    [No Abstract]   [Full Text] [Related]  

  • 20. Compulsive singing: another aspect of punding in Parkinson's disease.
    Bonvin C; Horvath J; Christe B; Landis T; Burkhard PR
    Ann Neurol; 2007 Nov; 62(5):525-8. PubMed ID: 17696122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.